AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18500419 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 70
Study 15593387 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐TRODAT‐1 SPECT imaging
Number of subjects: 38
Study 15593387 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched normal controls)
Number of subjects: 38
Study 12805079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ADMA
Number of subjects: 12
Study 10536648 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic running + Hormone Replacement Therapy (HRT)
Number of subjects: 43
Study 10536648 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic running
Number of subjects: 43
Study 10536648 — intervention group
Group type: COMPARATOR
Intervention: Control group (Postmenopausal without HRT)
Number of subjects: 43
Study 8777095 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O-free anaesthetic
Number of subjects: 2478
Study 8777095 — intervention group
Group type: COMPARATOR
Intervention: N2O regimen
Number of subjects: 2478
Study 1836232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic thermometers
Number of subjects: 96
Study 1836232 — intervention group
Group type: COMPARATOR
Intervention: Mercury-in-glass axillary thermometers
Number of subjects: 96
Study 1836232 — intervention group
Group type: COMPARATOR
Intervention: Electronic axillary thermometers
Number of subjects: 96
Study 1836232 — intervention group
Group type: COMPARATOR
Intervention: Mercury and electronic axillary methods
Number of subjects: 96
Study 6120945 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 6120945 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker (metoprolol or oxprenolol)
Number of subjects: 0
Study 29871544 — intervention group
Group type: EXPERIMENTAL
Intervention: Music & Memory (M&M) program
Number of subjects: 59
Study 29871544 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study 30694715 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide significant associations with DlCO
Number of subjects: 0
Study 30694715 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestive associations with DlCO
Number of subjects: 0
Study 30694715 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously reported COPD loci associated with DlCO
Number of subjects: 0
Study 28007924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole 750 mg plus miconazole 200 mg for 5 consecutive nights each month for 12 months
Number of subjects: 221
Study 28007924 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 consecutive nights each month for 12 months
Number of subjects: 221
Study 25965846 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment group (ITG) received 325 mg/day of ferrous sulphate daily.
Number of subjects: 22
Study 25965846 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study 25965846 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment group (ITG)
Number of subjects: 22
Study 23812622 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) during tourniquet deflation
Number of subjects: 70
Study 23812622 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PLR) during tourniquet deflation
Number of subjects: 70
Study 21536810 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiometer developed for hearing tests in a conference room
Number of subjects: 30
Study 21536810 — intervention group
Group type: COMPARATOR
Intervention: Clinical audiometer in a soundproof room
Number of subjects: 30
Study 19678442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB)
Number of subjects: 84
Study 19678442 — intervention group
Group type: COMPARATOR
Intervention: One Step (OS)
Number of subjects: 84
Study 17972381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0
Study 17972381 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE0118
Number of subjects: 0
Study 17972381 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioidergic system modulation
Number of subjects: 0
Study 15741988 — intervention group
Group type: EXPERIMENTAL
Intervention: Two portions of fruits and vegetables (2 FV) daily for 14 days
Number of subjects: 39
Study 15741988 — intervention group
Group type: COMPARATOR
Intervention: Five portions of fruits and vegetables (5 FV) daily for 14 days
Number of subjects: 39
Study 11971103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (n = 9)
Number of subjects: 19
Study 11971103 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n = 10)
Number of subjects: 19
Study 9468162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 microg/kg/min)
Number of subjects: 0
Study 9468162 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine alone
Number of subjects: 0
Study 8562146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomudex 3.0 mg/m2 given once every 3 weeks
Number of subjects: 439
Study 8562146 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2 for 5 days (the Mayo regimen), given every 4‐5 weeks
Number of subjects: 439
Study 8562146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomudex
Number of subjects: 439
Study 8562146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 439
Study 2698941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim 1.5 mg
Number of subjects: 13
Study 2698941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1152354 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin tablets
Number of subjects: 0
Study 1152354 — intervention group
Group type: COMPARATOR
Intervention: Digitoxin elixir
Number of subjects: 0
Study 31523848 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated call
Number of subjects: 568
Study 31523848 — intervention group
Group type: COMPARATOR
Intervention: Personal call
Number of subjects: 568
Study 30284519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient cocktail composed of polyphenols, omega‐3 fatty acids, vitamin E, and selenium
Number of subjects: 20
Study 30284519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient cocktail
Number of subjects: 20
Study 30284519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 20
Study 28422709 — intervention group
Group type: EXPERIMENTAL
Intervention: Living within 600 meters of high voltage power lines
Number of subjects: 285
Study 28422709 — intervention group
Group type: COMPARATOR
Intervention: Control group (living farther than 600 meters from power lines)
Number of subjects: 285
Study 25630040 — intervention group
Group type: EXPERIMENTAL
Intervention: KD-247 8mg/kg
Number of subjects: 0
Study 25630040 — intervention group
Group type: EXPERIMENTAL
Intervention: KD-247 16mg/kg
Number of subjects: 0
Study 25630040 — intervention group
Group type: EXPERIMENTAL
Intervention: KD-247 (all doses)
Number of subjects: 0
Study 25630040 — intervention group
Group type: EXPERIMENTAL
Intervention: KD-247 (16mg/kg)
Number of subjects: 0
Study 23510091 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (8 mg kg(‐1) h(‐1))
Number of subjects: 10
Study 23510091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21525253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA ground beef (3.21 g more 18:1(n-9), 1.26 g less 18:0, 0.89 g less 16:0, and 0.36 g less 18:1(trans) fatty acids per patty)
Number of subjects: 27
Study 21525253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-MUFA ground beef
Number of subjects: 27
Study 19625785 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (18,000 pulses over 3 weeks) + Citalopram (20 mg/day for 9 weeks)
Number of subjects: 62
Study 19625785 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment + Citalopram (20 mg/day for 9 weeks)
Number of subjects: 62
Study 16699970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of glucagon
Number of subjects: 100
Study 16699970 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of scopolamine butylbromide
Number of subjects: 100
Study 15056110 — intervention group
Group type: EXPERIMENTAL
Intervention: Light orthodontic forces (25 g)
Number of subjects: 10
Study 15056110 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy orthodontic forces (225 g)
Number of subjects: 10
Study 15056110 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral teeth)
Number of subjects: 10
Study 11806864 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glycine treatment
Number of subjects: 33
Study 11806864 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics (clozapine or olanzapine)
Number of subjects: 33
Study 9742977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood-glucose control with metformin (n=342)
Number of subjects: 1704
Study 9742977 — intervention group
Group type: COMPARATOR
Intervention: Addition of metformin in sulphonylurea-treated patients (n=268)
Number of subjects: 1704
Study 9742977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of metformin-allocated patients
Number of subjects: 1704
Study 7738908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (3.6 mM)
Number of subjects: 28
Study 7738908 — intervention group
Group type: COMPARATOR
Intervention: Control (without pentoxifylline)
Number of subjects: 28
Study 7738908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 28
Study 7738908 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 7738908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and Control
Number of subjects: 28
Study 2929979 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sublingual nifedipine after weaning from bypass
Number of subjects: 20
Study 2929979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2929979 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sublingual nifedipine
Number of subjects: 20
Study 4591000 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (Symmetrel)
Number of subjects: 100
Study 4591000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29620722 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Number of subjects: 2095
Study 29620722 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 2095
Study 27965306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional (IL) injection
Number of subjects: 54
Study 27965306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranodal (IN) injection
Number of subjects: 54
Study 27965306 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intralesional and intranodal (ILN) injection
Number of subjects: 54
Study 27965306 — intervention group
Group type: EXPERIMENTAL
Intervention: DCIS patients
Number of subjects: 54
Study 27965306 — intervention group
Group type: EXPERIMENTAL
Intervention: IBC patients
Number of subjects: 54
Study 27965306 — intervention group
Group type: EXPERIMENTAL
Intervention: DCIS patients who achieved pCR
Number of subjects: 54
Study 27965306 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients who achieved pCR
Number of subjects: 54
Study 25387312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 0
Study 25387312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 0
Study 25387312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) with tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 0
Study 25387312 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ABC/3TC and TDF/FTC
Number of subjects: 0
Study 25387312 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ABC/3TC and TDF/FTC at high viral loads
Number of subjects: 0
Study 23276806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 698
Study 23276806 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 698
Study 23276806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Number of subjects: 698
Study 23276806 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 698
Study 21621992 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. for 12 weeks
Number of subjects: 0
Study 21621992 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0
Study 17368912 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually masked associates presented at rapid rates during study phase.
Number of subjects: 0
Study 17368912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstudied test words presented for perceptual identification.
Number of subjects: 0
Study 17368912 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate tests after studying each list of associates.
Number of subjects: 0
Study 16418872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowatinex 200 mg t.i.d.
Number of subjects: 0
Study 16418872 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 600 mg t.i.d.
Number of subjects: 0
Study 12945875 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin once daily
Number of subjects: 0
Study 10580782 — intervention group
Group type: EXPERIMENTAL
Intervention: Current users of lipid-lowering medications
Number of subjects: 630
Study 10580782 — intervention group
Group type: EXPERIMENTAL
Intervention: Past users of lipid-lowering medications
Number of subjects: 630
Study 10580782 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users of lipid-lowering medications)
Number of subjects: 630
Study 8656503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine-zidovudine combination therapy (300 mg lamivudine every 12 hours + 200 mg zidovudine every 8 hours for 24 weeks)
Number of subjects: 129
Study 8656503 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy for 24 weeks
Number of subjects: 129
Study 2252184 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscularly
Number of subjects: 20
Study 2252184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7010528 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium (Biogastrone tablets) 100 mg three times a day for 4 weeks, continued for another 4 weeks if ulcers were not healed
Number of subjects: 40
Study 7010528 — intervention group
Group type: COMPARATOR
Intervention: Dummy tablets (control group)
Number of subjects: 40
Study 7010528 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg three times a day
Number of subjects: 40
Study 31834128 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended automated office blood pressure (AOBP)
Number of subjects: 2588
Study 31834128 — intervention group
Group type: COMPARATOR
Intervention: Auscultatory BP
Number of subjects: 2588
Study 31834128 — intervention group
Group type: COMPARATOR
Intervention: Attended oscillometric AOBP
Number of subjects: 2588
Study 31834128 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended AOBP
Number of subjects: 2588
Study 31151334 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt needle
Number of subjects: 108
Study 31151334 — intervention group
Group type: COMPARATOR
Intervention: Sharp needle
Number of subjects: 108
Study 28007444 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐session educational intervention with written materials provided in English or Spanish
Number of subjects: 52
Study 28007444 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 52
Study 25779222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - three sessions in 3 months
Number of subjects: 29
Study 25779222 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 29
Study 25098969 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued medications
Number of subjects: 450
Study 22839577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained low efficiency dialysis using a single-pass batch dialysis system (SLED-BD)
Number of subjects: 232
Study 22839577 — intervention group
Group type: COMPARATOR
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 232
Study 22839577 — intervention group
Group type: EXPERIMENTAL
Intervention: SLED-BD
Number of subjects: 232
Study 22839577 — intervention group
Group type: COMPARATOR
Intervention: CVVH
Number of subjects: 232
Study 19749003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF-DPI) 400 microg (1 x 400 microg/inhalation; treatment B)
Number of subjects: 0
Study 19749003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF-DPI) 400 microg (2 x 200 microg/inhalation; treatment A)
Number of subjects: 0
Study 19749003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two inhalations; treatment C)
Number of subjects: 0
Study 17652247 — intervention group
Group type: EXPERIMENTAL
Intervention: 5A's intervention
Number of subjects: 2177
Study 17652247 — intervention group
Group type: EXPERIMENTAL
Intervention: 3A's intervention
Number of subjects: 2177
Study 17652247 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2177
Study 15784639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dilution on-line haemofiltration (HF)
Number of subjects: 40
Study 15784639 — intervention group
Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD)
Number of subjects: 40
Study 11888956 — intervention group
Group type: EXPERIMENTAL
Intervention: Home unattended polysomnography (H‐PSG)
Number of subjects: 99
Study 11888956 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography performed in a local hospital and telemonitored by a sleep laboratory (T‐PSG)
Number of subjects: 99
Study 11888956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for H‐PSG
Number of subjects: 99
Study 11888956 — intervention group
Group type: COMPARATOR
Intervention: Patient preference for T‐PSG
Number of subjects: 99
Study 11888956 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of sleep and respiratory indexes
Number of subjects: 99
Study 11888956 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance of H‐PSG and T‐PSG
Number of subjects: 99
Study 10210343 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-section computed tomography (CT)
Number of subjects: 34
Study 7607973 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant extracorporeal photochemotherapy (ECP)
Number of subjects: 163
Study 7607973 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin/cyclophosphamide
Number of subjects: 163
Study 7607973 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 163
Study 7607973 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapies (ECP and doxorubicin/cyclophosphamide)
Number of subjects: 163
Study 3138056 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 39
Study 3138056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 39
Study 3138056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazepham (20 mg)
Number of subjects: 39
Study 3138056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30708393 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 24
Study 30708393 — intervention group
Group type: COMPARATOR
Intervention: No Milrinone (Control)
Number of subjects: 24
Study 31377075 — intervention group
Group type: EXPERIMENTAL
Intervention: GC3114 (high-dose, quadrivalent influenza vaccine)
Number of subjects: 100
Study 31377075 — intervention group
Group type: COMPARATOR
Intervention: Control (standard-dose quadrivalent influenza vaccine)
Number of subjects: 100
Study 26994300 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide infusion (1.5 µg/min)
Number of subjects: 40
Study 26321502 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose epirubicin and cyclophosphamide (SDE) (8 × 60 mg/m(2))
Number of subjects: 777
Study 26321502 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose epirubicin and cyclophosphamide (HDE) (8 × 100 mg/m(2))
Number of subjects: 777
Study 26321502 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, fluorouracil (CMF)
Number of subjects: 777
Study 24217684 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 88
Study 24217684 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 88
Study 24217684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 88
Study 21360584 — intervention group
Group type: EXPERIMENTAL
Intervention: EtO‐sterilized non‐cross‐linked Reflection All-Poly cups
Number of subjects: 150
Study 21360584 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxinium femoral heads
Number of subjects: 150
Study 21360584 — intervention group
Group type: COMPARATOR
Intervention: Charnley Ogee acetabular cup
Number of subjects: 150
Study 18630561 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-strand semitendinosus tendon autograft
Number of subjects: 42
Study 18630561 — intervention group
Group type: COMPARATOR
Intervention: LARS artificial ligament
Number of subjects: 42
Study 20553629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa leaf extract (1 gm/day for 90 days)
Number of subjects: 60
Study 20553629 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, similar amount for 90 days)
Number of subjects: 60
Study 16118787 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 99
Study 16118787 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 99
Study 16118787 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study 12117043 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg bd
Number of subjects: 85
Study 12117043 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg bd
Number of subjects: 85
Study 12117043 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (Theo-Dur 300 mg bd)
Number of subjects: 85
Study 12117043 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 85